hERG Channels: From Antitargets to Novel Targets for Cancer Therapy

Annarosa Arcangeli1, Andrea Becchetti2

  • 1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. annarosa.arcangeli@unifi.it.

Insights

Targeting the hERG K+ channel shows promise for cancer therapy by affecting neoplastic progression. However, strategies are needed to prevent fatal arrhythmias caused by hERG channel blockade.

Area of Science:

  • Oncology
  • Cardiology
  • Molecular Biology

Background:

  • The human Ether-à-go-go-Related Gene (hERG) K+ channel plays a role in neoplastic progression.
  • Blockade of the hERG channel exhibits anticancer effects in preclinical models.

Discussion:

  • hERG channel blockade can lead to fatal cardiac arrhythmias in humans.
  • Developing cancer therapies targeting hERG requires careful consideration of cardiotoxicity.

Key Insights:

  • Evidence is presented on mitigating cardiotoxicity associated with hERG channel targeting in cancer treatment.
  • Understanding hERG channel function is crucial for safe and effective cancer therapies.

Outlook:

  • Future research should focus on selective hERG inhibitors or alternative therapeutic strategies.
  • Clinical translation of hERG-targeted cancer therapies necessitates robust safety protocols to manage cardiac risks.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K